Starch/Poly(glycerol-adipate) Nanocomposites: A Novel Oral Drug Delivery Device
Source abstract
Abstract
Biocompatible and bio-based materials are an appealing resource for the pharmaceutical industry. Poly(glycerol-adipate) (PGA) is a biocompatible and biodegradable polymer that can be used to produce self-assembled nanoparticles (NPs) able to encapsulate active ingredients, with encouraging perspectives for drug delivery purposes. Starch is a versatile, inexpensive, and abundant polysaccharide that can be effectively applied as a bio-scaffold for other molecules in order to enrich it with new appealing properties. In this work, the combination of PGA NPs and starch films proved to be a suitable biopolymeric matrix carrier for the controlled release preparation of hydrophobic drugs. Dynamic Light Scattering (DLS) was used to determine the size of drug-loaded PGA NPs, while the improvement of the apparent drug water solubility was assessed by UV-vis spectroscopy. In vitro biological assays were performed against cancer cell lines and bacteria strains to confirm that drug-loaded PGA NPs maintained the effective activity of the therapeutic agents. Dye-conjugated PGA was then exploited to track the NP release profile during the starch/PGA nanocomposite film digestion, which was assessed using digestion models mimicking physiological conditions. The collected data provide a clear indication of the suitability of our biodegradable carrier system for oral drug delivery.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: biodegradable polymer synthesis and properties · Polysaccharides Composition and Applications · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Chemistry, University of Nottingham, University Park, Nottingham NG7 2RD, UK
School of Chemistry, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
School of Pharmacy, University of Nottingham, University Park, Nottingham NG7 2RD, UK
School of Life and Medical Sciences, University of Hertfordshire, College Lane, Hatfield AL10 9AB, UK
Institut de Chimie et des Matériaux Paris-Est (ICMPE), Systèmes Polymères Complexes, UMR CNRS 7182, 2-8 rue Henri Dunant, 94320 Thiais, France
Department of Pharmacy, University of Genoa, Viale Benedetto XV 3, 16132 Genoa, Italy
Department of Food Science, Faculty of Science, University of Copenhagen, Rolighedsvej 26, 1958 Frederiksberg C, Denmark
Funding
European Research Council · EPSRC · Danish council of research · Italian MIUR project PRIN 2017
References (52)
Show source-provided references
1. Liu, L.S., Kost, J., Yan, F., and Spiro, R.C. (2012). Hydrogels from biopolymer hybrid for biomedical, food, and functional food applications. Polymers (Basel).10.3390/polym4020997 ↗
2. Swainson, S.M.E., Styliari, I.D., Taresco, V., and Garnett, M.C. (2019). Poly (glycerol adipate) (PGA), an enzymatically synthesized functionalizable polyester and versatile drug delivery carrier: A literature update. Polymers (Basel), 11.10.3390/polym11101561 ↗
3. (2019). Sagnelli; Cavanagh; Xu; Swainson; Blennow; Duncan; Taresco; Howdle Starch/poly (glycerol-adipate) nanocomposite film as novel biocompatible materials. Coatings, 9.10.3390/coatings9080482 ↗
4. Variation in structure and properties of poly(glycerol adipate) via control of chain branching during enzymatic synthesis10.1016/j.polymer.2016.02.036 ↗
5. Polymeric micelles for oral drug delivery10.1016/j.ejpb.2010.06.007 ↗
6. Pharmacokinetic aspects of nanoparticle-in-matrix drug delivery systems for oral/buccal delivery10.3389/fphar.2019.01057 ↗
7. Vasanthan, T., and Hoover, R. (2009). Barley starch: Production, properties, modification and uses. Starch, 601–628.10.1016/B978-0-12-746275-2.00016-1 ↗
8. The molecular structures of starch components and their contribution to the architecture of starch granules: A comprehensive review10.1002/star.201000013 ↗
9. Plant-crafted starches for bioplastics production10.1016/j.carbpol.2016.07.039 ↗
10. Helix-breaking news: Fighting crystalline starch energy deposits in the cell10.1016/j.tplants.2010.01.009 ↗
11. Properties of FDA-approved small molecule protein kinase inhibitors10.1016/j.phrs.2019.03.006 ↗
12. (2019, October 22). FDA-Approved Protein Kinase Inhibitors/US Food and Drug Administration Approved Small Molecule Protein Kinase Inhibitors. Available online: http://webcache.googleusercontent.com/search?q=cache:http://www.brimr.org/PKI/PKIs.htm.
13. (2019, October 21). Search of: Kinase Inhibitors | Recruiting, Not yet Recruiting, Active, not Recruiting, Enrolling by Invitation Studies - List Results - ClinicalTrials.gov, Available online: https://clinicaltrials.gov/ct2/results?term=kinase+inhibitors&Search=Apply&recrs=b&recrs=a&recrs=f&recrs=d&age_v=&gndr=&type=&rslt=.
14. Kinase-targeted cancer therapies: Progress, challenges and future directions10.1186/s12943-018-0804-2 ↗
15. Variability in bioavailability of small molecular tyrosine kinase inhibitors10.1016/j.ctrv.2015.03.005 ↗
16. (2019, October 22). Pharmacokinetic Considerations and Challenges in Oral Anticancer Drug Therapy | Perspective Article | Pharmaceutical Journal. Available online: https://www.pharmaceutical-journal.com/research/perspective-article/pharmacokinetic-considerations-and-challenges-in-oral-anticancer-drug-therapy/20206478.article?firstPass=false.
17. The kinase inhibitor SI113 induces autophagy and synergizes with quinacrine in hindering the growth of human glioblastoma multiforme cells10.1186/s13046-019-1212-1 ↗
18. Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell lines10.1016/j.ejmech.2019.07.048 ↗
19. Combining X-ray crystallography and molecular modeling toward the optimization of pyrazolo[3,4-d]pyrimidines as potent c-Src inhibitors active in vivo against Neuroblastoma10.1021/jm5013159 ↗
20. Design, synthesis, and biological evaluation of pyrazolo[3,4-d]pyrimidines active in vivo on the Bcr-Abl T315I mutant10.1021/jm400233w ↗
21. Identification of potent c-Src inhibitors strongly affecting the proliferation of human neuroblastoma cells10.1016/j.bmcl.2011.07.079 ↗
22. Water solubility enhancement of pyrazolo[3,4-d]pyrimidine derivatives via miniaturized polymer-drug microarrays10.1021/acsmedchemlett.7b00456 ↗
23. Synthesis and antimicrobial activity of newly synthesized 4-substituted-pyrazolo[3,4-d]pyrimidine derivatives10.1007/s00044-017-1814-0 ↗
24. Molecular iodine promoted synthesis of new pyrazolo[3,4-d]pyrimidine derivatives as potential antibacterial agents10.1016/j.ejmech.2009.10.051 ↗
25. Novel pyrazolo[3,4-d]pyrimidine-based inhibitors of Staphlococcus aureus DNA polymerase III: Design, synthesis, and biological evaluation10.1021/jm020483c ↗
26. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs10.1016/j.chembiol.2010.04.012 ↗
27. Dong, Q., Luo, J., Qiu, W., Cai, L., Anjum, S., Li, B., Hou, M., Xie, G., and Sun, G. (2016). Inhibitory effect of camptothecin against rice bacterial brown stripe pathogen acidovorax avenae subsp. avenae RS-2. Molecules, 21.10.3390/molecules21080978 ↗
28. The structural basis of camptothecin interactions with human serum albumin: Impact on drug stability10.1021/jm00027a005 ↗
29. Camptothecin prodrug block copolymer micelles with high drug loading and target specificity10.1039/C4PY00369A ↗
30. Nanocapsule formation by interfacial polymer deposition following solvent displacement10.1016/0378-5173(89)90281-0 ↗
31. Low glycaemic index foods from wild barley and amylose-only barley lines10.1016/j.jff.2017.11.028 ↗
32. The Smallest Intestine (TSI) - A low volume in vitro model of the small intestine with increased throughput10.1093/femsle/fny231 ↗
33. An Automated force field Topology Builder (ATB) and repository: Version 1.010.1021/ct200196m ↗
34. Testing and validation of the Automated Topology Builder (ATB) version 2.0: Prediction of hydration free enthalpies10.1007/s10822-014-9713-7 ↗
35. Definition and testing of the GROMOS force-field versions 54A7 and 54B710.1007/s00249-011-0700-9 ↗
36. Force field evaluation for biomolecular simulation: Fenthalpies of solvation of polar and apolar compounds in various solvents10.1002/cphc.200500510 ↗
37. Pullman, B. (1981). Interaction models for water in relation to protein hydration. Intermolecular Forces: Proceedings of the Fourteenth Jerusalem Symposium on Quantum Chemistry and Biochemistry Held in Jerusalem, Israel, April 13-16, 1981, Springer.10.1007/978-94-015-7658-1 ↗
38. Particle mesh Ewald: An N·log(N) method for Ewald sums in large systems10.1063/1.464397 ↗
39. A smooth particle mesh Ewald method10.1063/1.470117 ↗
40. Gordhan, D., Swainson, S.M.E., Pearce, A.K., Styliari, I.D., Lovato, T., Burley, J.C., Garnett, M.C., and Taresco, V. (2019). Poly(glycerol adipate): From a functionalized nanocarrier to a polymeric-prodrug matrix to create amorphous solid dispersions. J. Pharm. Sci.10.1016/j.xphs.2019.12.004 ↗
41. A simple and efficient method for polymer coating of iron oxide nanoparticles10.1016/j.jddst.2019.101460 ↗
42. Exploring the enzymatic degradation of poly(glycerol adipate)10.1016/j.ejpb.2019.07.015 ↗
43. Poly(triazolyl methacrylate) glycopolymers as potential targeted unimolecular nanocarriers10.1039/C9NR05836B ↗
44. Multiscale modeling of drug-polymer nanoparticle assembly identifies parameters influencing drug encapsulation efficiency10.1021/ct501152a ↗
45. In silico screening for solid dispersions: The trouble with solubility parameters and χFH10.1021/acs.molpharmaceut.8b00637 ↗
46. Heterogeneity of malignant cells from a human colonic carcinoma
47. Classification of human colorectal adenocarcinoma cell lines
48. Epigenetic and genetic features of 24 colon cancer cell lines10.1038/oncsis.2013.35 ↗
49. A Landscape of therapeutic cooperativity in KRAS mutant cancers reveals principles for controlling tumor evolution10.1016/j.celrep.2017.07.006 ↗
50. EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: Retro- and prospective observations in non-small-cell lung cancer10.1093/annonc/mdl323 ↗
51. Mitogen-activated protein kinase phosphatase-1 inhibition and sustained extracellular signal-regulated kinase 1/2 activation in camptothecin-induced human colon cancer cell death10.4161/cbt.26044 ↗
52. Washington, N., Washington, C., and Wilson, C.W. (2000). Physiological Pharmaceutics, Barriers to Drug Absorption, CRC Press. [2nd ed.].10.1201/9780203483701 ↗